Literature DB >> 14616419

Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

N R Labiris1, M B Dolovich.   

Abstract

Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.

Mesh:

Substances:

Year:  2003        PMID: 14616419      PMCID: PMC1884297          DOI: 10.1046/j.1365-2125.2003.01893.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  64 in total

1.  Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.

Authors:  N M Concessio; M M VanOort; M R Knowles; A J Hickey
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 2.  Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative.

Authors:  M Nakanishi; A Noguchi
Journal:  Adv Drug Deliv Rev       Date:  2001-11-19       Impact factor: 15.470

3.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Effect of nebulizer type and antibiotic concentration on device performance.

Authors:  A Weber; G Morlin; M Cohen; J Williams-Warren; B Ramsey; A Smith
Journal:  Pediatr Pulmonol       Date:  1997-04

5.  Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler.

Authors:  S P Newman; F Morén; E Trofast; N Talaee; S W Clarke
Journal:  Eur Respir J       Date:  1989-03       Impact factor: 16.671

6.  Problems patients have using pressurized aerosol inhalers.

Authors:  G K Crompton
Journal:  Eur J Respir Dis Suppl       Date:  1982

Review 7.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  Evaluation of jet nebulisers for use with gentamicin solution.

Authors:  S P Newman; P G Pellow; M M Clay; S W Clarke
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

9.  A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects.

Authors:  K R Chapman; L Love; H Brubaker
Journal:  Chest       Date:  1993-11       Impact factor: 9.410

10.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols.

Authors:  S P Newman; D Pavia; N Garland; S W Clarke
Journal:  Eur J Respir Dis Suppl       Date:  1982
View more
  66 in total

1.  Feasibility of tissue plasminogen activator formulated for pulmonary delivery.

Authors:  John S Dunn; Rajiv Nayar; Jackie Campos; Brooks M Hybertson; Yue Zhou; Mark Cornell Manning; John E Repine; Kathleen A Stringer
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 2.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 3.  Particle transport and deposition: basic physics of particle kinetics.

Authors:  Akira Tsuda; Frank S Henry; James P Butler
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

Review 4.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 5.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

Review 6.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 7.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 8.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

9.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

10.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.